Jorna
Lv41
485 积分
2021-10-18 加入
-
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
12小时前
已完结
-
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
12小时前
已完结
-
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
8天前
已完结
-
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
8天前
已完结
-
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
8天前
已完结
-
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
8天前
已完结
-
Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
8天前
已完结
-
INTENSIVE CANCER CHEMOTHERAPY
10天前
已完结
-
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
10天前
已完结
-
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
10天前
已完结